- Home
- GPCR vs TNDM Comparison
GPCR vs TNDM Comparison
Compare GPCR & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- TNDM
- Stock Information
- Founded
- GPCR 2016
- TNDM 2006
- Country
- GPCR United States
- TNDM United States
- Employees
- GPCR N/A
- TNDM N/A
- Industry
- GPCR
- TNDM Medical/Dental Instruments
- Sector
- GPCR
- TNDM Health Care
- Exchange
- GPCR Nasdaq
- TNDM Nasdaq
- Market Cap
- GPCR 1.6B
- TNDM 1.9B
- IPO Year
- GPCR 2023
- TNDM 2013
- Fundamental
- Price
- GPCR $27.06
- TNDM $35.15
- Analyst Decision
- GPCR Strong Buy
- TNDM Buy
- Analyst Count
- GPCR 7
- TNDM 16
- Target Price
- GPCR $81.29
- TNDM $52.06
- AVG Volume (30 Days)
- GPCR 1.0M
- TNDM 1.1M
- Earning Date
- GPCR 03-07-2025
- TNDM 02-26-2025
- Dividend Yield
- GPCR N/A
- TNDM N/A
- EPS Growth
- GPCR N/A
- TNDM N/A
- EPS
- GPCR N/A
- TNDM N/A
- Revenue
- GPCR N/A
- TNDM $854,351,000.00
- Revenue This Year
- GPCR N/A
- TNDM $23.98
- Revenue Next Year
- GPCR N/A
- TNDM $10.89
- P/E Ratio
- GPCR N/A
- TNDM N/A
- Revenue Growth
- GPCR N/A
- TNDM 10.75
- 52 Week Low
- GPCR $23.50
- TNDM $21.85
- 52 Week High
- GPCR $62.74
- TNDM $53.69
- Technical
- Relative Strength Index (RSI)
- GPCR 42.52
- TNDM 48.69
- Support Level
- GPCR $23.50
- TNDM $34.51
- Resistance Level
- GPCR $27.68
- TNDM $38.28
- Average True Range (ATR)
- GPCR 1.71
- TNDM 1.78
- MACD
- GPCR 0.20
- TNDM -0.22
- Stochastic Oscillator
- GPCR 51.30
- TNDM 20.76
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.